Subscribe

Keeping Cost Out of the Drug Approval Debate

VBCC - Media Library - Pricing
Andrew Stainthorpe, PhD

The FDA has a regulatory function, which is probably best kept without looking at the costs of the medicines. The role is probably best for an independent HTA organization, like NICE. In Europe, the role of the EMA and of the HTA organization are 2 separate things, and that model works very well there.

Related Items
Benefits of the Single Payer Perspective
Andrew Stainthorpe, PhD
VBCC - Media Library published on March 25, 2015 in Payer-Provider
Weighing Cost and Care: An Oncologist's Debate
Andrew Stainthorpe, PhD
VBCC - Media Library published on March 25, 2015 in Personalized Medicine
Bringing the Patient into the Conversation
Andrew Stainthorpe, PhD
VBCC - Media Library published on March 25, 2015 in Personalized Medicine
Using Research to Guide Quality and Quantity of Care
Andrew Stainthorpe, PhD
VBCC - Media Library published on March 25, 2015 in Personalized Medicine
Affordability + Clinical Effectiveness = The Value Equation
C. Daniel Mullins, PhD
VBCC - Media Library published on March 25, 2015 in Pricing
Providing Patients with Cost Information
C. Daniel Mullins, PhD
VBCC - Media Library published on March 25, 2015 in Pricing
New Conversations About Costs of Cancer Care
C. Daniel Mullins, PhD
VBCC - Media Library published on March 25, 2015 in Pricing
Value-Based Concerns of European Oncologists
Andrew Stainthorpe, PhD
VBCC - Media Library published on March 25, 2015 in Pricing
Approaches to Alleviating Costs for Patients and Payers
Andrew Stainthorpe, PhD
VBCC - Media Library published on March 25, 2015 in Pricing
Value-Based Concerns - What Matters?
Linda Bosserman, MD, FACP
VBCC - Media Library published on March 25, 2015 in Pricing
Last modified: September 29, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology